Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline

Kucharzik, Torsten; Dignaß, Axel; Atreya, Raja; Bokemeyer, Bernd; Esters, Philip; Herrlinger, Klaus; Kannengießer, Klaus; Kienle, Peter; Langhorst, Jost; Lügering, Andreas; Schreiber, Stefan; Stallmach, Andreas; Stein, Jürgen M.; Sturm, Andreas; Teich, Niels; Siegmund, Britta

doi:10.1055/a-1296-3444

Cited by 52 publications

(53 citation statements)

References 777 publications

(794 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risikofaktoren für eine Infektion waren unter anderem der Gebrauch von Steroiden, Infliximab, Adalimumab, Metronidazol, Hospitalisationen und Komorbiditäten 143 . Die Empfehlungen zur Diagnostik und Therapie einer C. difficile- Infektion bei Patient*innen mit CED sind im Abschnitt „Infektiologische Probleme“ der Leitlinie Colitis ulcerosa 144 ausführlich dargestellt.…”

Section: Crohn – Leitlinie Ag 01 Diagnostik Und Initialdiagnostikunclassified

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Sturm

Atreya

Bettenworth³

et al. 2022

Z Gastroenterol

Self Cite

View full text Add to dashboard Cite

Kinder und Jugendliche Fertilität Medikamente in der Schwangerschaft und Stillzeit Entbindung Impfungen des Neugeborenen Der*die ältere CED-Patient*in M. Crohn -Leitlinie AG 07 Ernährung Ernährung Ernährung als Krankheitsauslöser beim M. Crohn Ernährung als ein den Krankheitsverlauf modulierender Faktor Ernährung als therapeutischer Ansatz bei Patient*innen mit M. Crohn Ernährung zur Behandlung von Defiziten bzw. Mangelzuständen

show abstract

Section: Crohn – Leitlinie Ag 01 Diagnostik Und Initialdiagnostikunclassified

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Sturm

Atreya

Bettenworth³

et al. 2022

Z Gastroenterol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Over the last 10 years a more specific and, moreover, individual endoscopic strategy was implemented in national IBD guidelines focusing on defined risk factors. In Germany, surveillance colonoscopy in UC starts 6–8 years after initial diagnosis and should be performed between each year in high-risk patients and every 4 year in patients with low-risk conditions ( 10 ), (level 1, grade A). Recently patients with primary sclerosing cholangitis (PSC), a tubular colon and those with a history of neoplasia were identified as having a higher risk for developing colorectal cancer and in these patients targeted and additional random biopsies were recommended during chromoendoscopy ( 11 ), (level 1, grade A).…”

Section: High-definition Endoscopy and Chromoendoscopy In Ibdmentioning

confidence: 99%

Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy

et al. 2021

Self Cite

View full text Add to dashboard Cite

High-definition endoscopy is one essential step in the initial diagnosis of inflammatory bowel disease (IBD) characterizing the extent and severity of inflammation, as well as discriminating ulcerative colitis (UC) from Crohn's disease (CD). Following general recommendations and national guidelines, individual risk stratification should define the appropriate surveillance strategy, biopsy protocol and frequency of endoscopies. Beside high-definition videoendoscopy the application of dyes applied via a spraying catheter is of additional diagnostic value with a higher detection rate of intraepithelial neoplasia (IEN). Virtual chromoendoscopy techniques (NBI, FICE, I-scan, BLI) should not be recommended as a single surveillance strategy in IBD, although newer data suggest a higher comparability to dye-based chromoendoscopy than previously assumed. First results of oral methylene blue formulation are promising for improving the acceptance rate of classical chromoendoscopy. Confocal laser endomicroscopy (CLE) is still an experimental but highly innovative endoscopic procedure with the potential to contribute to the detection of dysplastic lesions. Molecular endoscopy in IBD has taken application of CLE to a higher level and allows topical application of labeled probes, mainly antibodies, against specific target structures expressed in the tissue to predict response or failure to biological therapies. First pre-clinical and in vivo data from label-free multiphoton microscopy (MPM) are now available to characterize mucosal and submucosal inflammation on endoscopy in more detail. These new techniques now have opened the door to individualized and highly specific molecular imaging in IBD in the future and pave the path to personalized medicine approaches. The quality of evidence was stated according to the Oxford Center of evidence-based medicine (March 2009). For this review a Medline search up to January 2021 was performed using the words “inflammatory bowel disease,” “ulcerative colitis,” “crohn's disease,” “chromoendoscopy,” “high-definition endoscopy,” “confocal laser endomicroscopy,” “confocal laser microscopy,” “molecular imaging,” “multiphoton microscopy.”

show abstract

“…Die höchste altersspezifische Inzidenz liegt zwischen 16 und 25 Jahren. Auch hier erfolgt die Diagnose durch Anamnese, Sonografie und Endoskopie [2].…”

Section: Formen Chronisch Entzündlicher Darmerkrankungenunclassified

Care of Women with Chronic Inflammatory Bowel Disease (Chronic IBD) During Pregnancy

Kühnert

Kuschel

Kehl

et al. 2021

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

The incidence of chronic inflammatory bowel disease (chronic IBD) in persons of reproductive age is high. Chronic IBD does not typically lead to impaired fertility. Nevertheless, the percentage of women suffering from chronic IBD who have children is lower than that of the general population, due to self-imposed childlessness. Providing women with open, unbiased information and, if necessary, helping them to overcome baseless fears should therefore be an essential part of preconception counseling. With the exception of methotrexate, most standard drugs can and should be continued during pregnancy. If the pregnancy occurs during an inactive phase of disease, the rate of complications in pregnancy should, in principle, not be higher than normal. Nevertheless, pregnant women with chronic IBD are classed as high-risk pregnancies. Organ screening in accordance with DEGUM II criteria should be carried out in every case, and women must be monitored for the potential development of placental insufficiency. Any flare-ups which occur during pregnancy should be treated in full. Vaginal delivery can be considered if there is no perianal manifestation of disease; however, the individual risk must be carefully weighed up.

show abstract

Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline

Cited by 52 publications

References 777 publications

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004

Innovative Diagnostic Endoscopy in Inflammatory Bowel Diseases: From High-Definition to Molecular Endoscopy

Care of Women with Chronic Inflammatory Bowel Disease (Chronic IBD) During Pregnancy

Contact Info

Product

Resources

About